Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?

Thromb Res. 2016 Jul:143:101-2. doi: 10.1016/j.thromres.2016.05.003. Epub 2016 May 7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use
  • Anticoagulants / therapeutic use*
  • Aspirin / therapeutic use*
  • Female
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Humans
  • Lenalidomide
  • Male
  • Multiple Myeloma / complications*
  • Multiple Myeloma / drug therapy
  • Risk Factors
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use
  • Thrombosis / etiology*
  • Thrombosis / prevention & control*
  • Vitamin K / antagonists & inhibitors*

Substances

  • Angiogenesis Inhibitors
  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Vitamin K
  • Thalidomide
  • Lenalidomide
  • Aspirin